Ekterly

(Sebetralstat)

PreclinicalSmall molecule

KKalVista Pharmaceuticals, Ltd.

Ekterly is one of 10 small molecule programs targeting Angioedema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

AngioedemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Angioedema

#DrugCompanyPhaseTrials

Firazyr

Takeda

Approved

3 2

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—3

Deucrictibant

PPharvaris Netherlands B.V.

Phase 3

2 4

Januvia

ZZydus Therapeutics Inc.

Preclinical

1 5

Heparin Sodium

BBaxter Healthcare Corporation

Substance P

1 7

Glucagon Like Peptide-1

UUniversity Hospital, Gentofte, Copenhagen

Preclinical

1 8

Bradykinin

VVanderbilt University

Preclinical

1 9

Ekterly

KKalVista Pharmaceuticals, Ltd.

Preclinical

1 10

Brain Natriuretic Peptide

MMayo Clinic

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Angioedema1 trial

Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Approved for marketing·KKalVista Pharmaceuticals, Ltd.··NCT06628713

Hereditary Angioedema1 trial

On Demand Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With Hereditary Angioedema (HAE) With Sebetralstat

Available·KKalVista Pharmaceuticals, Ltd.··NCT07216378

Regulatory

FDA Approval Timeline[4]

Jul 3, 2025

EKTERLY

NDA NDA219301

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sebetralstat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sebetralstat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sebetralstat. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219301). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Ekterly. U.S. Food & Drug Administration.
[6]
SEC EDGAR — KalVista Pharmaceuticals, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKalVista Pharmaceuticals, Ltd.

Patent Landscape[5]

Patent Cliff

Nov 26, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10364238Nov 26, 2035

11001578Nov 26, 2035

11198691Nov 26, 2035

11084809Nov 26, 2035

10611758Nov 26, 2035

3 more patents

11739068Jun 23, 2037

11230537Dec 25, 2037

11234939Jan 26, 2039

Ekterly

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Angioedema1 trial

Hereditary Angioedema1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News